Reducing Complement Inhibition to Treat Leukemia and Lymphoma

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,645,906.00
Award Year:
2013
Program:
SBIR
Phase:
Phase II
Contract:
2R44CA162582-02
Award Id:
n/a
Agency Tracking Number:
R44CA162582
Solicitation Year:
2013
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
PAI Life Sciences Inc., 1616 Eastlake Ave E Ste 550, SEATTLE, WA, 98102-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
148051621
Principal Investigator:
DARRICK CARTER
(206) 623-0331
darrick.carter@proteinai.com
Business Contact:
DARRICK CARTER
(206) 623-0331
darrick.carter@proteinai.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): Funding of this application will move a new combination cancer therapy for leukemia and lymphomas towards human clinical trials. Monoclonal antibodies, mAbs have emerged as a rapidly growing class of oncology therapeutics. Despite their success in certain clinical applications, the therapeutic efficacy of mAbs is limited, with only a minority of patients responding to these agents as therapies on their own. It is becoming clear that many tumors evade successful elimination by co-opting the body's own immune regulatory systems. These same mechanisms also reduce the anti-cancer effects of mAbs. We are developing a molecule that addresses one of these key mechanisms that improves the therapeutic effects of mAbs by: 1) increasing sensitivity of cancers to treatment; 2) unmasking resistant cancers so they again become sensitized; and 3) possibly allowing treatment of cancers that have become refractory to therapy. This could make mAb therapy more effective, and potentially reduce the amounts of mAbs required for treatment, thus reducing costs and potential side effects. The public health implications of improving rituximab treatment are significant. There are over 300,000 patients with non-Hodgkins lymphoma (NHL), and the majority receives treatment with rituximab either alone or combined with chemotherapy. Many patients develop recurrent diseases, and 5-year survival rates for NHL is 63%. In most cases of tumor recurrence, patients develop resistance to rituximab therapy. Theimmediate goal of the research is to collect data to enable an Investigational New Drug (IND) filing on a combination therapy for lymphoma. Our consultant at the University of Washington has collected a significant body of information supporting the superiority of the combination of depleting CD46 on the cell surface with antibody therapy in blood cancers Our long-term goal is to translate the technology from research bench to clinical bedside leading to enhancement of monoclonal antibody (mAb) therapy.PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Although monoclonal antibody therapy can be an effective way to treat cancer, further progress is needed to increase therapeutic success. We intend to enhance cancer therapy to improve treatment worldwide.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government